Jimmy Suttie

A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets

N. Kasabov, L. Kavalieris, A. Kamat, 2015, BMC Medical Research Methodology.

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study

Y. Lotan, S. Shariat, J. Raman, 2017, The Journal of urology.

Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician–Patient Real-World Clinical Data Analysis

P. O'sullivan, Jimmy Suttie, D. Darling, 2018, Oncology and Therapy.

Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis

P. O'sullivan, Carthika Luxmanan, Jimmy Suttie, 2018, BMC Urology.

Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma

P. O'sullivan, Carthika Luxmanan, Jimmy Suttie, 2017, Advances in Therapy.

Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.

Y. Lotan, J. Raman, L. Kavalieris, 2017, Urologic oncology.

A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma

L. Kavalieris, P. O'sullivan, P. Gilling, 2015, BMC Urology.